Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine by Albuquerque, Andreia de et al.
Original Article · Originalarbeit
Breast Care 2012;7:7–12 Published online: February 21, 2012
DOI: 10.1159/000336548
PD Dr. med. Nikos Fersis
Klinik für Frauenheilkunde und Geburtshilfe
Klinikum Chemnitz gGmbH
Flemmingstrasse 4, 09116 Chemnitz, Germany
Tel. +49 371 333 22-200, Fax -121
n.fersis@skc.de / andreia.de.albuquerque@gmail.com
© 2012 S. Karger GmbH, Freiburg
1661-3791/12/0071-0007$38.00/0
Accessible online at: 
www.karger.com/brc
Fax +49 761 4 52 07 14
Information@Karger.de
www.karger.com
BreastCare
Multimarker Analysis of Circulating Tumor Cells in 
 Peripheral Blood of Metastatic Breast Cancer Patients: 
A Step Forward in Personalized Medicine
Andreia de Albuquerquea,b Sepp Kaulb Georg Breiera Petra Krabischc Nikos Fersisc
aDepartment of Pathology, Faculty of Medicine Carl Gustav Carus, University of Dresden, 
bDepartment of Molecular Biology, Zentrum für Diagnostik, Chemnitz, 
cDepartment of Gynaecology and Obstetrics, Klinikum Chemnitz, Germany
Schlüsselwörter
Tumorzellen, zirkulierende · Mammakarzinom, 
 metastatisches · Immunomagnetische Zellisolierung · 
 Real-Time Reverse Transkription Polymerase- 
Kettenreaktion · Genexpressionsanalyse
Zusammenfassung
Ziel: Entwicklung eines immunomagnetischen Verfah-
rens zur Isolierung zirkulierender Tumorzellen (CTCs) in 
Kombination mit einer molekularen Multimarkeranalyse 
für die hochspezifische Identifizierung maligner Zellen. 
Patientinnen und Methoden: Peripheres Blut (PB) von 
32 Patientinnen mit metastasiertem Mammakarzinom 
und von 42 gesunden Kontrollen wurde für die immuno-
magnetische Tumorzellanreicherung mit den Antikör-
pern BM7 und VU1D9 genutzt. Eine Real-Time Reverse 
Transkription Polymerase-Kettenreaktion (RT-PCR)- 
Methodik mit den Markern KRT19, SCGB2A2, MUC1, 
EPCAM, BIRC5 und ERBB2 wurde für den CTC-Nachweis 
und die Tumorzellcharakterisierung entwickelt. Ergeb­
nisse: Für die einzelnen Marker wurden die folgenden 
Positivitätsraten ermittelt: 46,9% für KRT19, 25,0% für 
SCGB2A2, 28,1% für MUC1, 28,1% für EPCAM, 21,9% 
für BIRC5 und 15,6% für ERBB2. Nach der Bestimmung 
individualisierter Cut-off-Werte ergab sich für den kom-
binierten Multimarkernachweis eine Sensitivität und 
Spezifität von 56,3% bzw. 100%. Bemerkenswert war der 
Befund, dass 27,0% der HER2-tumornegativen Patientin-
nen ERBB2-mRNA-positive CTCs aufwiesen. Schluss­
folgerung: Die hier beschriebene Methodik bestimmt 
CTCs mit hoher Spezifität. Die molekulare Multimarker-
analyse liefert wertvolle Real-Time-Informationen für 
personalisierte Behandlungsmodalitäten.
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Summary
Aim: To develop an immunomagnetic assay for the 
 isolation of circulating tumor cells (CTCs) followed by 
the analysis of a multimarker panel, which will enable 
the characterization of these malignant cells with high 
accuracy. Patients and Methods: Peripheral blood (PB) 
was collected from 32 metastatic breast cancer patients 
and 42 negative controls. The antibodies BM7 and 
VU1D9 were used for immunomagnetic tumor cell en-
richment. A real-time reverse transcription-polymerase 
chain reaction (RT-PCR) approach for the markers KRT19, 
SCGB2A2, MUC1, EPCAM, BIRC5 and ERBB2 was used 
for CTC detection and characterization. Results: The pos-
itivity rates for each marker were as follows: 46.9% for 
KRT19, 25.0% for SCGB2A2, 28.1% for MUC1, 28.1% for 
EPCAM, 21.9% for BIRC5, and 15.6% for ERBB2. After the 
creation of individualized cutoffs, the sensitivity and spe-
cificity of the combined marker gene panel increased to 
56.3% and 100%, respectively. Interestingly, 27.0% of the 
HER2-negative tumor patients showed ERBB2 mRNA-
positive CTCs. Conclusions: The described technique can 
be used to measure CTCs with great accuracy. The use 
of a multimarker panel for the characterization of CTCs 
may provide real-time information and be of great value 
in therapy monitoring.
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Introduction
Breast cancer (BC) is one of the most common diagnosed 
 malignancies in women, being the second leading cause of 
cancer-related deaths in the female population worldwide [1]. 
Despite improvements and significant advances in BC treat-
ment and screening, still 5% of the patients exhibit clinically 
detectable metastatic lesions and 30–40% have occult metas-
tases that will possibly lead to a bad prognosis and disease 
 relapse [2].
Women with metastatic BC (MBC) represent a heteroge-
neous group with varying prognosis. However, even if at-
tempts have been made to stratify MBC patients into various 
prognostic groups using traditional prognostic indices, these 
data are often limited and not accurate enough to predict 
 survival rates [3] considering that breast tumors are character-
ized by their heterogeneity. In addition, it is also well known 
that systemic chemotherapy is toxic and in some cases of low 
 effectivity [4, 5]. Therefore, it is important to develop novel 
methods that would allow the proper selection of patients 
for a given type of systemic treatment and predict their out-
come [6].
Prospective studies have demonstrated that detection of 
circulating tumor cells (CTCs) in MBC can successfully pre-
dict progression-free survival (PFS) and overall survival (OS) 
[7, 8]. CTCs are tumor cells that can detach from the primary 
tumor, extravasate, circulate into the bloodstream, reach dis-
tant organs and potentially give rise to metastasis [9]. Indeed, 
CTCs provide a link between the primary tumor and the 
 metastatic lesions, which may contain precious information. 
However, isolation of CTCs has proven to be difficult since 
these malignant cells are rare events occurring at rates as low 
as 1 cell per 105–107 peripheral blood (PB) mononucleated 
cells [10]. Several methods have been developed to detect 
CTCs in the blood of patients with different malignant carci-
nomas, with each one having unique advantages and limita-
tions. However, no enrichment or detection method has yet 
proven to be the golden standard, and continuing efforts are 
needed to improve the sensitivity and reliability of CTC 
 detection techniques. One of the most common techniques 
available for the isolation of CTCs relies on the separation 
of specific cell subsets in a magnetic field when they are 
 labeled by specific antibodies conjugated with magnetic parti-
cles – immunomagnetic separation – followed by real-time 
reverse transcription-polymerase chain reaction (real-time 
RT-PCR), a technique that provides a high analytical sensitiv-
ity, by enabling the detection of a single tumor cell among 107 
normal cells [11]. In addition to detection and enumeration, 
molecular characterization of CTCs provides a very promising 
application in oncology. The tumor phenotype can change 
during the course of the disease, and CTCs might function as 
real-time biopsies [12–14]. These observations led us to con-
duct this pilot study, which aims to develop an immunomag-
netic assay for the isolation of CTCs, followed by the analysis 
of a tumor-specific marker gene panel using real-time RT-
PCR; this will enable the characterization of these malignant 
cells and perhaps contribute to a more individualized treat-
ment approach. The selected marker panel comprises the fol-
lowing genes: KRT19, SCGB2A2, MUC1, EPCAM, BIRC5, 
and ERBB2. Extensive assay validation experiments were 
conducted in order to address technical concerns, such as spe-
cificity, sensitivity and efficiency, and to obtain the highest 
 accuracy for the assay.
Patients and Methods
Patients
Clinically confirmed MBC patients were recruited. The study was ap-
proved by the local ethics committee (ethic-vote 473–2006 and DETECT 
2007) and was conducted in concordance with the declaration of Helsinki. 
All patients enrolled provided their written informed consent.
PB Sampling
From all MBC patients, 10.0-ml whole blood samples were collected, be-
fore treatment, during routine blood sampling into ethylenediamine-
tetraacetic acid (EDTA) tubes (Sarstedt AG and Co, Nümbrecht, Ger-
many), and the CTCs were isolated within 4 h of specimen collection. 
A group of 42 healthy, anonymous control subjects, who were randomly 
selected from the hospital staff, were asked to participate in the study, 
and blood sampling was performed as described above.
Cell Culture
The tumor cells lines T47D, MCF7 and SKBR3, obtained from the Amer-
ican Type Culture Collection, and the human breast carcinoma cell line 
ZE, obtained by isolation of a primary tumor tissue (T3, N2, G3, HER2 3 
plus) after 15–20 culture passages, having a HER2 gene amplification 
level of > 5 (determined by fluorescence in situ hybridization (FISH)) and 
being surprisingly homogeneous in the expression of several breast tu-
mor-associated genes including KRT19, SCGB2A2, MUC1, EPCAM, 
BIRC5, and ERBB2, were used in this study. The cells were preserved 
and cultured in 75-cm2 tissue culture flasks using Dulbecco’s modified 
Eagle medium (DMEM; Invitrogen, Karlsruhe, Germany) supplemented 
with 8% fetal calf serum (FCS), 0.5% penicillin-streptomycin, at 37 °C in 
a 5% CO2 environment. Log phase cells were collected at < 90% conflu-
ence by trypsin digestion and used for spiking and dilution experiments.
Embedded Tumor Cell Calibrators
In order to control the efficiency and robustness of the assay, 10 ZE 
tumor cells were spiked into matching calibrator probes and negative 
donor probes by microscope-controlled micromanipulation. These cali-
bration tests were performed routinely and spiked probes were analyzed 
by real-time RT-PCR for the marker genes KRT19, SCGB2A2, MUC1, 
EPCAM, BIRC5, and ERBB2.
Immunomagnetic Enrichment Antibodies
In this assay, two antibodies were used for immunomagnetic separation of 
CTCs in PB: the commercially available VU1D9, a high-affinity antibody 
reactive with a fixation-resistant epitope of the membrane protein 
EpCAM, and our own antibody BM7 [15], the epitope of which is the 
glycopeptide APDTRPAP, substituted with N-acetylgalactosamine on 
the threonine of the tandem repeat structure of the tumor-associated 
 underglycosylated mucin-1.
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CTC Isolation from Blood Samples
CTCs were isolated from PB using 200 mL of BM7/VU1D9 antibodies 
coupled directly to immunomagnetic 4-micron Dynabeads® (Invitrogen, 
Karlsruhe, Germany). The beads were incubated with the PB on a low-
speed rotating device for 20 min at room temperature, after which the 
l abeled cells were separated using an external magnetic particle concen-
trator (MPC). The bead fraction was washed 5 times with phosphate-buff-
ered salt solution (PBS) and the retained mucin-1+ and/or EpCAM+ cells 
were lysed in 400 ml Tris-HCl lysis buffer (included in the Dynabeads® 
mRNA DirectTM kit; Invitrogen, Karlsruhe, Germany) and stored at 
–85 °C until mRNA isolation and cDNA synthesis.
mRNA Isolation and cDNA Synthesis
mRNA isolation from the lysed enriched cells was performed with the 
Dynabeads® mRNA DIRECTTM kit according to the manufacturer’s 
 instructions. Sensiscript® Reverse Transcriptase (Qiagen, Hilden, Ger-
many), recommended for first-strand cDNA synthesis using < 50 ng 
RNA, was used for reverse transcription of the isolated and purified 
mRNA in combination with the Dynabeads® oligo(dT)25 primer (Invitro-
gen, Karlsruhe, Germany), according to the manufacturer’s guidelines. 
Reverse transcription was performed in 0.5 ml RNasin® ribonuclease in-
hibitor (40 U/ml; Promega, Mannheim, Germany), 4 ml RT buffer, 4 ml 
dNTPs (5 mM each), 2 ml Sensiscript reverse transcriptase, in a thermocy-
cler under the following conditions: 60 min at 37 °C followed by 5 min at 
93 °C. The resulting 40 ml of cDNA was stored at –20 °C until further use.
Multimarker Real-Time PCR Analysis
Reverse transcription resulted in cDNA, which was the template for 
tumor cell detection and characterization by real-time PCR. The analysis 
of tumor-associated mRNA isolated from CTCs was performed for 
KRT19, SCGB2A2, MUC1, EPCAM, BIRC5, and ERBB2. Primers were 
selected using the Universal ProbeLibrary® system, and their sequences 
can be seen in table 1. The selected primers were designed to be intron 
spanning (exon specific), to eliminate reactivity with genomic DNA. The 
amplification of ACTB (primers: forward 5’-GAAGAGCCAAG-
GACAGGTAC-3’; reverse 5’-CAACTTCATCCACGTTCACC-3’) 
served as a reference internal control and was used to verify the integrity 
of the RNA and the quality of the samples. PCR amplifications were per-
formed on the Rotor-Gene 3000 in a total volume of 25 ml. Each reaction 
contained 12.5 ml reaction buffer MESA FAST qPCR MasterMix Plus for 
SYBR® assay (Eurogentec, Köln, Germany), including dNTPs (together 
with dUTP), MeteorTaq DNA polymerase, MgCl2 (4 mM final concen-
tration), SYBR® Green I and stabilizers, 0.1 ml of each primer (100 pmol/
ml), 2 ml cDNA and 10.3 ml of RNase-free H2O. The thermal profile used 
for real-time PCR was as follows: After a 5-min denaturation step at 
95 °C, 40 cycles were carried out by denaturation at 95 °C for 5 s, anneal-
ing at 59 °C for 20 s and extension for 12 s at 72 °C. Cell line cDNA was 
included as a positive control for the evaluation of the PCR reaction and 
positivity of the tumor-associated transcripts.
PCR efficiency, linearity and sensitivity of each gene was validated 
with a standard curve constructed from a simultaneously run serially 
 diluted cDNA pool of human PB lymphocytes (PBL) and the tumor cell 
line ZE, which expresses all the gene markers analyzed in this assay. 
 Negative controls included samples without reverse transcriptase and 
samples where the cDNA was replaced with genomic DNA. All values 
were obtained from the quantitative cycle (Cq) at which the increase in 
SYBR green fluorescent signal associated with an exponential increase of 
PCR products reached the fixed threshold value of 0.25.
Random PCRs were analyzed by gel electrophoresis in order to deter-
mine the specificity of the assay and to ensure that, under the PCR condi-
tions and with the different primer sets used, the product of the expected 
size was amplified.
Marker Gene Cutoff
In this study, 6 marker genes that are known to be overexpressed in 
breast cancer and other adenocarcinoma types [16–18] were selected 
based on literature relevance, and their expression in CTCs was analyzed 
through real-time PCR. However, in order to obtain accurate results, in-
formation about the analytical sensitivity of the assay must be established. 
Therefore, to determine the analytical limit of detection, serial 10-fold di-
lutions of a cDNA pool of human PBL and ZE tumor cells were used to 
construct standard curves. Dilutions were tested in quintuplicate and the 
corresponding Cq value obtained as the lower analytical limit of detection 
for each gene was selected as the analytical cutoff.
Statistical Analysis
The linearity, efficiency and analytical sensitivity of the real-time RT-
PCR assay were assessed by linear regression analysis. Standard curves 
were constructed for each marker, and from the equation obtained after 
regression analysis, the following parameters were determined: sensitiv-
ity, given by the y-intercept; linearity, expressed as the correlation coeffi-
cient (R2); and efficiency of the assay, determined by the slope of the log-
linear phase of the amplification reaction. All data were analyzed using 
SPSS® (version 17.0; SPSS, Chicago, IL, USA).
Results
Assay Validation
To determine the linearity, efficiency and analytical sensitivity 
of the multimarker real-time RT-PCR assay, we analyzed se-
rial 10-fold dilutions of a cDNA pool of human PBL and ZE 
tumor cells, in 5 different experiments for the 5 tumor-associ-
ated transcripts: KRT19, SCGB2A2, MUC1, EPCAM, 
BIRC5, and ERBB2. The calibration curves from these data 
showed linearity over the entire quantification range (1–104 
Table 1. Primer sequences of the 6 tumor-associated transcripts
Marker NM reference Primer sequence Location Product size
KRT19 NM_002276.2 forward: GCCACTACTACACGACCATCC 525–545, exon 1 126 bp
reverse: CAAACTTGGTTCGGAAGTCAT 650–630, exon 2/3
SCGB2A2 NM_002411.21 forward: CTCCCAGCACTGCTACGC 95–112, exon 1 72 bp
reverse: TGTGGATTGTCTTGGAAA 158–145, exon 2
MUC1 NM_002456.4 forward: TCGTAGCCCCTATGAGAAGG 795–814, exon 7/8 71 bp
reverse: CCACTGCTGGGTTTGTGTAA 865–846, exon 8
EPCAM NM_002354.2 forward: CGTCAATGCCAGTGTACTTCA 448–508, exon 2 88 bp
reverse: TTTCTGCCTTCATCACCAAA 575–553, exon 3
BIRC5 NM_001168.2 forward: GCCCAGTGTTTCTTCTGCTT 284–303, exon 2 86 bp
reverse: CCGGACGAATGCTTTTTATG 369–350, exon 3
ERBB2 NM_004448.2 forward: GGGAAACCTGGAACTCACCTA 409–429, exon 2 75 bp
reverse: CCCTGCACCTCCTGGATA 483–466, exon 3
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will enable the characterization of these malignant cells and 
perhaps will contribute to a more individualized treatment ap-
proach. To improve the reliability of CTC analysis by real-
time RT-PCR, we performed a preanalytical enrichment 
using the tumor-specific antibodies VU1D9 and BM7 with 
high affinity for the antigens EpCAM and mucin-1, respec-
tively, and employed a panel of tumor-associated marker 
genes. When combining the analyses of the KRT19, 
SCGB2A2, MUC1, EPCAM, BIRC5, and ERBB2 mRNAs 
and creating individualized gene cutoffs, a total of 56.3% 
MBC patients were found positive for at least 1 mRNA 
marker, while no amplification of the marker genes was seen 
in the 42 analyzed healthy controls. Moreover, data obtained 
from the embedded tumor cell calibrators and dilution experi-
ments showed that tumor cells could be consistently detected 
at a level as low as 2 cells, indicating that the developed im-
munomagnetic assay followed by the amplification of a panel 
of genes using real-time RT-PCR is a feasible and sensitive 
technique for CTC detection. It is also important to underline 
that, among the positive patients, even when grouped accord-
ing to their prognostic indices, there was heterogeneity in 
marker expression: Not all the samples were positive for the 6 
tumor cells) and R2 ≥ 0.99 in all of the cases, indicating a pre-
cise log-linear relationship. The PCR efficiency, expressed as 
E = 10–1/slope ranged from 96 to 104% for the multimarker 
panel. The analytical sensitivity was estimated as the last 
 serial linear concentration that yielded positives in all 5 repli-
cates, and the corresponding Cq value was selected as the 
 analytical cutoff. According to the results obtained, the ana-
lytical Cq cutoff under which a sample is considered to be 
positive for the corresponding marker gene was defined as: 
36.0 for KRT19, 37.3 for SCGB2A2, 37.1 for MUC1, 36.0 for 
EPCAM, 35.0 for BIRC5, and 37.9 for ERBB2.
Embedded Tumor Cell Calibrator Results
Tumor cells from one cell line of a primary breast carcinoma 
(ZE) and from established cell lines – T47D, MCF7 and 
SKBR3 – were spiked into blood from negative controls 
and matched calibrator samples in order to evaluate the effi-
ciency and robustness of the assay. We analyzed 60 samples 
spiked with 2 tumor cells and 40 samples spiked with 10 tumor 
cells. All tumor cells were reliably identified at the level of 
10 tumor cells in 5 ml of blood, and the detection rate for 
2 tumor cells in 5 ml of blood was 92%.
Patients’ Samples
Blood samples were obtained from 32 MBC patients, accord-
ing to a standardized procedure. The inclusion criteria were 
as follows: women with histological diagnosis of breast cancer, 
evidence of metastatic disease from imaging studies, starting a 
new line of therapy, and/or already treated for the advanced 
disease. Line and type of therapy were not used as selection 
criteria in this study. The demographic data and the clinico-
pathological characteristics of all patients are summarized in 
table 2.
Expression of the Multimarker Panel in MBC Patients
A total of 56.3% of the analyzed MBC patients had a positive 
signal in at least 1 cancer-associated marker gene in their PB 
sample. Individualized gene positivity rates were as follows: 
46.9% for KRT19, 25.0% for SCGB2A2, 28.1% for MUC1, 
28.1% for EPCAM, 21.9% for BIRC5, and 15.6% for ERBB2. 
No amplification of the marker genes was seen in the 42 ana-
lyzed healthy controls. Interestingly, 27.0% of the patients 
with HER2-negative tumors had ERBB2 mRNA-positive 
CTCs, and patients among the same prognostic groups 
showed different CTC marker profiles. A detailed description 
of the marker positivity according to site of metastasis and 
 receptor status can be seen in figure 1.
Discussion
In the present study, we developed an immunomagnetic assay 
for the isolation of CTCs, followed by the analysis of a tumor-
specific marker gene panel using real-time RT-PCR, which 
Table 2. Demographic and clinical description of the MBC patients
Variable
Breast patients
n %
Total number of patients 32
Age at study entry, years
Median 60.6
Range 41–80
Tumor size
T1  6 18.8
T2 15 46.9
T3  5 15.6
T4  3  9.4
Unknown  3  9.4
Lymph nodes
N0  9 28.1
≥ N1 20 62.5
Unknown  3  9.4
Histology grade
G1  2  6.3
G2 15 46.9
G3 11 34.4
Unknown  4 12.5
Histology
Ductal 13 40.6
Lobular  6 18.8
Other  4 12.5
Unknown  9 28.1
Site of metastasis at study entrya
Visceral  9 28.1
Nonvisceral 14 43.8
Both  9 28.1
Receptor status
ER and/or PR positive 16 50.0
HER2 positive/ER/PR negative  9 28.1
ER/PR/HER2 negative  6 18.8
aVisceral sites included lung, liver, brain, adrenal glands, pancreas and 
pleura (with or without effusions). Nonvisceral sites included breast, 
lymph nodes, chest wall, bone, and skin.
ER = Estrogen receptor, PR = progesterone receptor.
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markers are needed to achieve the maximum sensitivity for 
the assay, their inclusion may be extremely relevant once the 
selected genes used for characterization of the CTCs have 
been proved by others to be overexpressed in adenocarcino-
mas and to be indicators of poor prognosis. KRT19, coding 
for a cytoskeletal component present in normal and cancerous 
epithelial cells [19], is expressed in the majority of breast car-
cinomas [20] and has been extensively used as a marker for 
CTC detection [19], due to its high sensitivity. The expression 
of ERBB2 was revealed to be often coupled with cytokeratin-
positive CTCs, which makes ERBB2 a valid marker for the 
identification of CTCs [21]. MUC1 has been found to be aber-
rantly expressed and underglycosylated in many tumor tissues 
like breast tumors and it is associated with poor prognosis 
[22]. The EPCAM product is involved in signaling processes, 
gene regulation, and cellular metabolism [23], appearing to be 
overexpressed by the majority of human epithelial carcinomas 
[24]. Indeed, it was shown that EPCAM expression in primary 
breast cancers was associated with poor clinical outcome, and 
in vitro studies confirmed that the specific ablation of 
EPCAM expression using RNA interference results in a dra-
matic decrease in the invasive potential of breast cancer cell 
lines [25], making EPCAM a candidate for molecular therapy. 
Another study has shown that the BIRC5 mRNA measured 
by real-time RT-PCR in the primary tumor had a strong and 
independent prognostic value in breast cancer and might be 
used as a marker to stratify breast cancer patients for better 
treatment modalities [26].
Several clinicopathological factors such as tumor size, tumor 
grade, and histological type, HER2/neu overexpression, lym-
phovascular invasion (LVI) and hormone receptor status are 
known to have a clear prognostic utility in cancer. However, 
in the era of targeted therapies, the use of a biological para-
meter instead of the classical prognostic parameters may bet-
ter fit to the current clinical challenges [27]. Genetic analyses 
have shown genetic disparities between the primary tumor 
and the metastatic lesions. Our study revealed that 27.0% of 
the patients with HER2/neu-negative tumors had ERBB2 
mRNA-positive CTCs, a fact that supports the previous state-
ment. Therefore, monitoring CTCs seems to be an important 
tool that might identify women who were initially ineligible 
for herceptin but who would later qualify for the drug.
The goal of therapy for most patients with MBC is basi-
cally palliative. Yet, once a treatment regimen is selected for a 
patient, it is continued until either toxicity or evidence of pro-
gression is identified. Thus, there is a need for improvement 
of the prognostic tools used in the management of MBC pa-
tients [28, 29]. Metastatic spread represents the ultimate cause 
of death, and in some cases, patients thought to have a local-
ized disease may in fact present occult metastasis, most likely 
derived from CTCs, which will lead to disease progression. 
Following this idea, the detection and analysis of CTCs may 
play an extremely important role in the diagnosis, prognosis 
and management of MBC patients.
markers, neither did all the patients exhibit the same positive 
markers with the same level of expression, and this highlights 
the need for the use of a multimarker gene panel. However, 
some markers were not singly expressed in any of the ana-
lyzed samples, meaning that their use will not increase the 
sensitivity of the assay. However, our main goal was to de-
velop an assay that would not only identify CTCs with high 
specificity and sensitivity, but also to perform a phenotype 
characterization of these cells. We believe that the future of 
the CTC analysis relies on the development of assays that are 
capable of generating CTC molecular profiles that could dis-
tinguish CTCs with the capacity to metastasize and/or CTCs 
that can lead to therapy failure. Therefore, even if not all the 
Fig. 1. Marker positivity according to site of metastasis and 
receptor status.
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